This reply clarifies interpretations of valuation components in R&D firms, addressing concerns on computations and measurements.
Presents a reply to the clarification made by Joseph K. Cheung and Mandy Li on the author's interpretation of the component of the call option held by the research and development (R&D) firm with R&D limited partnerships. Difference between their measurements and computations.
No takes yet. Share an insight, caveat, or question.
Terry Shevlin (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: